GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (LTS:0RU5) » Definitions » Price-to-Funds-From-Operations

BerGenBio ASA (LTS:0RU5) Price-to-Funds-From-Operations : (As of Apr. 12, 2025)


View and export this data going back to 2017. Start your Free Trial

What is BerGenBio ASA Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


BerGenBio ASA Business Description

Industry
Traded in Other Exchanges
Address
Mollendalsbakken 9, Bergen, NOR, 5009
BerGenBio ASA is a clinical-stage biopharmaceutical Company focused on developing novel medicines for aggressive diseases. The company's clinical asset, bemcentinib, targeting the receptor tyrosine kinase AXL, is currently in development in a Ph1b/2a study in 1L STK 11 mutated NSCLC and preclinical development for severe respiratory infections.